An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

Simple Summary Currently, the treatment for localized colon cancer consists of surgery and,
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …

Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that
has come from primary or metastatic cancer sites. Neoplasm-specific genetic and epigenetic …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …

Background: Colorectal cancer is one of the most common cancers worldwide and has a
high mortality rate following disease recurrence. Treatment efficacy is maximized by …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …

Simple Summary There is currently a lack of useful tests to detect microscopic residual
disease in patients who have undergone surgery to remove their bowel cancer. This inability …

Purpose: Markers of chemotherapy efficacy in metastatic colorectal cancer (mCRC) are
essential for optimization of treatment strategies. We evaluated the applicability of early …

Colorectal cancer (CRC) is currently the most common type of cancer in Japan, and its
prognosis has improved because of development of diagnosis and advancement in …